Sign up to access all valuation multiples
Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Diagnostyka has a last 12-month revenue (LTM) of $602M and a last 12-month EBITDA of $156M.
In the most recent fiscal year, Diagnostyka achieved revenue of $533M and an EBITDA of $139M.
Diagnostyka expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Diagnostyka valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $602M | XXX | $533M | XXX | XXX | XXX |
| Gross Profit | $487M | XXX | $347M | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $156M | XXX | $139M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $105M | XXX | $87.7M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $67.5M | XXX | $61.0M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $150M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 4, 2025, Diagnostyka's stock price is PLN 202 (or $55).
Diagnostyka has current market cap of PLN 6.8B (or $1.9B), and EV of PLN 7.7B (or $2.1B).
See Diagnostyka trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $1.9B | XXX | XXX | XXX | XXX | $2.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 4, 2025, Diagnostyka has market cap of $1.9B and EV of $2.1B.
Diagnostyka's trades at 4.0x EV/Revenue multiple, and 15.2x EV/EBITDA.
Equity research analysts estimate Diagnostyka's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Diagnostyka has a P/E ratio of 27.7x.
See valuation multiples for Diagnostyka and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 13.5x | XXX | 15.2x | XXX | XXX | XXX |
| EV/EBIT | 20.1x | XXX | 24.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 27.7x | XXX | 30.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 27.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDiagnostyka's last 12 month revenue growth is 15%
Diagnostyka's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Diagnostyka's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Diagnostyka's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Diagnostyka and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 27% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diagnostyka acquired XXX companies to date.
Last acquisition by Diagnostyka was XXXXXXXX, XXXXX XXXXX XXXXXX . Diagnostyka acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| Where is Diagnostyka headquartered? | Diagnostyka is headquartered in Poland. |
| Is Diagnostyka publicy listed? | Yes, Diagnostyka is a public company listed on WAR. |
| What is the stock symbol of Diagnostyka? | Diagnostyka trades under DIA ticker. |
| When did Diagnostyka go public? | Diagnostyka went public in 2025. |
| Who are competitors of Diagnostyka? | Similar companies to Diagnostyka include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Diagnostyka? | Diagnostyka's current market cap is $1.9B |
| What is the current revenue of Diagnostyka? | Diagnostyka's last 12 months revenue is $602M. |
| What is the current revenue growth of Diagnostyka? | Diagnostyka revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Diagnostyka? | Current revenue multiple of Diagnostyka is 3.5x. |
| Is Diagnostyka profitable? | Yes, Diagnostyka is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Diagnostyka? | Diagnostyka's last 12 months EBITDA is $156M. |
| What is Diagnostyka's EBITDA margin? | Diagnostyka's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Diagnostyka? | Current EBITDA multiple of Diagnostyka is 13.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
